Yes. Esketamine nasal spray (Spravato) has been reimbursed by Ireland's HSE since January 2022 for treatment-resistant depression — but only a psychiatrist can initiate it, and delivery is concentrated in a limited number of specialist psychiatric services. For patients who qualify through public services, treatment is covered; the practical hurdles are the psychiatric referral and whether a programme runs in your area. This page covers exactly who qualifies, how the referral works, what you pay, and what to do if you fall outside the criteria; the eligibility decision itself always sits with a clinician, and you can begin orienting yourself with our eligibility check.
What is covered
Ireland approved reimbursement of esketamine nasal spray in January 2022, following confidential price negotiations between the HSE and the manufacturer after the national health-technology assessment (NCPE HTA ID 19055). The reimbursed indication is treatment-resistant major depressive disorder in adults — a moderate-to-severe episode that has not responded to adequate trials of antidepressants — used in combination with an SSRI or SNRI, per the EU label. Coverage runs through HSE specialist psychiatric services: you self-administer the spray under the direct supervision of a healthcare professional, followed by an observation period, all within the service.
Who qualifies
The Irish reimbursement follows the EU label indication:
- An adult with treatment-resistant major depressive disorder — a moderate-to-severe episode that has not responded to adequate trials of antidepressants, where "adequate" means sufficient dose for sufficient duration;
- Esketamine is used in combination with an SSRI or SNRI;
- Treatment is psychiatrist-initiated — a GP cannot start it.
The practical currency is a written treatment history: every antidepressant tried in the current episode, with substance, dose, duration and outcome, plus any augmentation and psychotherapy. That record is what turns "we could consider esketamine" into a scheduled assessment, so assemble it before any referral.
Who decides and how to apply
The decision to prescribe sits with a psychiatrist within HSE specialist psychiatric services. Your GP cannot start esketamine; their role — and it is an important one — is to refer you into psychiatric care with a documented treatment history that makes the assessment fast. The second gatekeeper is capacity: reimbursement is a funding decision, not a capacity decision, and uptake has been limited and clustered in specialist services, because supervised administration demands space, staff and a monitoring routine. Expect your psychiatrist to know whether a programme runs in your catchment area — and expect the honest answer in some regions to be "not yet"; Galway has been a visible growth point in the west. For the full picture of every legal route in the country, see our Ireland access guide; to see who is listed near you, browse providers in Ireland.
What it costs you
For patients who qualify through public specialist psychiatric services, treatment is covered — the medicine and its supervised administration are delivered within the HSE service rather than dispensed to you at a pharmacy. The gatekeepers are clinical, not financial: the psychiatrist's decision and a supervised-administration site with capacity in your area. Ireland's private market offers no priced alternative yet — the announced private ketamine programme publishes no prices — so there is no meaningful self-pay benchmark to quote.
If you do not qualify
Ireland has no named exceptional or individual-case reimbursement mechanism for esketamine — the standard criteria and the psychiatrist's judgment govern. The honest fallbacks are:
- The private route, which barely exists yet. Neuromed Clinic (Dublin and Galway) has announced a ketamine-assisted psychotherapy programme launching in autumn 2026, with no published prices or screening criteria. If you research it, ask for written costs and screening details first — our clinic-choice guide lists the questions.
- Clinical trials are free by definition, and Ireland's research scene is real: the Phase 3 CYB003 (EMBRACE) trial for major depressive disorder is recruiting at Tallaght in Dublin and La Nua in Galway, and trial screening can run in parallel with a public esketamine referral. See the trials guide for how to search.
Frequently asked questions
Is Spravato reimbursed in Ireland?
Yes — the HSE has reimbursed it since January 2022 for adults with treatment-resistant depression, in combination with an oral antidepressant. Treatment must be initiated by a psychiatrist and delivered through specialist psychiatric services with supervised administration.
Can my GP prescribe esketamine?
No. The decision to prescribe sits with a psychiatrist. Your GP's role is to refer you into secondary care with a documented treatment history — every antidepressant tried, with dose, duration and outcome — which makes the psychiatric assessment fast.
Why is it still hard to get if it is covered?
Reimbursement is a funding decision, not a capacity decision. Supervised administration demands space, staff and a monitoring routine, so delivery is concentrated in a limited number of specialist services and honest regional gaps exist. The Europe-wide reimbursement map shows the same pattern across most countries.
Is private ketamine therapy an option in Ireland?
Not as of July 2026. Neuromed Clinic (Dublin and Galway) has announced a ketamine-assisted psychotherapy programme launching in autumn 2026, without published prices — today you would be researching a waiting room, not a treatment.
Sources
- NCPE — Esketamine (Spravato) HTA ID 19055
- Irish Medical Times: Spravato approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder (2022)
- Blossom: Medical access in Ireland
- Blossom: Ireland country report
- EMA: Spravato (esketamine) EPAR
- Reimbursement Pathways for Psychedelic Therapies in Europe — Magnetar Access × Blossom (2025)
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations and reimbursement rules change; always verify current requirements with your insurer and discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.